OMass: Leadership Promotions Bolster Team for Strategic Advances

OMass Therapeutics, a biotechnology firm focused on developing medicines against complex biological targets, has announced two key leadership promotions. Dr. Hsin Loke has been promoted to the role of Chief Operating Officer, while Jon Roffey, Ph.D., has been elevated to Senior Vice President of Discovery and Non-Clinical operations. Both leaders bring a wealth of experience from notable biotech and pharmaceutical roles, enhancing OMass's capabilities in areas such as finance, operations, and drug discovery. Hsin Loke, who joined the company in 2018, has a strong background in finance and operational leadership, particularly within GSK's Rare Diseases Unit. Her appointment as COO reflects her effectiveness in advancing strategic goals at OMass. Jon Roffey, bringing over two decades of drug discovery experience from roles in oncology and CNS disorders, was previously the head of medicinal chemistry at OMass. His new title will see him continue to leverage the company's OdyssION platform in the development of innovative treatments for rare diseases. The OdyssION platform distinguishes itself by using advanced mass spectrometry techniques, allowing for precise drug-target interaction studies, leading to groundbreaking therapeutic solutions. These leadership changes occur as OMass continues to advance its pipeline, particularly with its MC2 receptor antagonist programs targeted at rare diseases like Congenital Adrenal Hyperplasia and Cushing's Syndrome. The company, headquartered in Oxford, UK, continues to enjoy substantial financial backing, having raised over $160 million from a mix of international investors.